Retatrutide in women: what the studies included
Reviewed 16 sourcesPublished by PepVault
Retatrutide in women: the share of women and ages in each trial, why Lilly capped women, how much more weight women lost, and why pregnancy was excluded.

- Last reviewed
- Sources
- 16
- Questions
- 7
- Compounds
- 3
The short answer
Women made up about half of retatrutide's trial participants: 48% in the phase 2 obesity trial and 48 to 63% in the phase 3 trials that report it, with women capped at about 70% by design. Where results were split by sex, women lost more: 20.3 kg on average in phase 2 against 16.0 kg for men. Pregnant and breastfeeding women were excluded.
Evidence: Randomized, placebo-controlled phase 1b, 2 and 3 trials in people, sponsored by Eli Lilly; the sex split comes from phase 2's subgroup analyses (a meeting report and a meta-analysis) and a TRIUMPH-1 meeting presentation. Retatrutide is investigational and not approved.

How many women were in the retatrutide trials?
Seven trials of retatrutide in people have reported who they enrolled. Retatrutide is one peptide that acts on three hormone receptors (GIP, GLP-1 and glucagon), made by Eli Lilly and still investigational. Every trial below was randomized and placebo-controlled, and every one was open to both sexes145791011.
| Trial | Who and how long | Women | Average age |
|---|---|---|---|
| Phase 1b, 202256 | 72 adults with type 2 diabetes, 12 weeks | Only women who could not become pregnant | Ages 20 to 70 could join |
| Phase 2 obesity, 202313 | 338 adults with obesity or overweight, 48 weeks | 163 (48.2%) | 48.2 years |
| Phase 2 type 2 diabetes, 20234 | 281 adults with type 2 diabetes, 36 weeks | 156 (56%) | 56.2 years |
| TRIUMPH-1, 2026710 | 2,339 adults with obesity, no diabetes, 80 weeks | Capped at about 70%; 435 (75.8%) in its knee-arthritis group | Not in the abstract; 56.1 years in the knee-arthritis group |
| TRIUMPH-2, 20269 | 1,152 adults with obesity and type 2 diabetes, 80 weeks | 554 (48%) | 55.1 years |
| TRIUMPH-4, 202610 | 445 adults with obesity and knee arthritis, 68 weeks | 282 (63.4%) | 55.2 years |
| TRANSCEND-T2D-1, 202611 | 537 adults with type 2 diabetes, 40 weeks | 296 (55%) | 48.8 years |
The caps are the surprise. Obesity trials usually fill up with women, so Lilly set the mix on purpose: phase 2 enrolled roughly equal shares of women and men by design13, and the phase 3 TRIUMPH program caps women at about 70% to make sure enough men take part810. Sex was also one of the factors the TRIUMPH trials balanced when they assigned people to a dose, so every arm got a similar mix of women and men810.
TRIUMPH-1's overall share of women and its average age are in the full NEJM paper, which we could not open; the 75.8% and 56.1 years are its knee-arthritis group of 574 people, reported in the TRIUMPH-4 paper10.

Do women lose more weight on retatrutide than men?
Yes, in every split published so far. The phase 2 obesity trial looked at weight change at 48 weeks in women and men separately, and the first phase 3 trial did the same at 80 weeks. The doses named are the trials' arms, not a dose for anyone.
| Result | Women | Men |
|---|---|---|
| Phase 2, all retatrutide arms, 48 weeks: average loss14 | 20.3 kg | 16.0 kg |
| Phase 2, best arm, 48 weeks13 | 28.5% (8 mg) | 21.9% |
| TRIUMPH-1, best arm, 80 weeks (meeting report)12 | Up to 30.8% | 23.2% |
In phase 2, women lost 4.2% more of their body weight than men once placebo was taken into account, a statistically significant gap (P = .019)13. A meta-analysis that pulled the trial's numbers for the 129 women and 139 men on retatrutide found the gap in kilograms too: 4.2 kg more for women14.
The first phase 3 trial points the same way. At the American Diabetes Association meeting in June 2026, the TRIUMPH-1 team presented weight loss at 80 weeks of up to 30.8% in women and 23.2% in men, and called it consistent with phase 212. That split comes from a news report of the talk, not the published paper; the paper's abstract gives no split by sex7.
PepVault keeps your weight log and your dose log side by side, so your own curve sits next to the trial averages instead of being guessed from memory. Track your weight in PepVault
Does retatrutide work for women over 50?
Women in their 50s are well represented. The phase 3 trials that report an average age landed between 48.8 and 55.2 years91011. Phase 2 was open to adults aged 18 to 75, with an average age of 48.23, and about half its participants (167 of 338) were 50 or older13.
In the phase 2 subgroup analysis, women aged 50 and older lost 8% more body weight than men of the same age, a statistically significant gap (P = .002); the report does not say whether that means percentage points13. Younger adults lost more than older ones overall, so age and sex pull in different directions for an older woman13.
None of the trials has published results split by menopause stage or by hormone therapy. Our guide to GLP-1s and menopause covers what the tirzepatide and semaglutide trials show there.
Were pregnant or breastfeeding women in the retatrutide trials?
No. The trials kept pregnancy out by design, so there are no human data on retatrutide in pregnancy or breastfeeding.
- Phase 1b: women could join only if they could not become pregnant, after menopause or surgical sterilization6.
- Phase 2 obesity: women who were pregnant, breastfeeding or planning a pregnancy were excluded, and women who could become pregnant needed adequate contraception3.
- Phase 3 TRIUMPH: pregnancy is one of the reasons to stop the study drug8.
Retatrutide's half-life is about 6 days5, so it stays in the body for weeks after the last injection. The approved GLP-1s carry their own pregnancy guidance on their labels, covered in our guide to GLP-1s and pregnancy.
When to get help If you are pregnant, planning a pregnancy or breastfeeding, the trials give no answer for retatrutide, and the decision belongs with your doctor; a positive pregnancy test while taking any drug of this class is a reason to call them that week.
Do side effects differ for women on retatrutide?
Little has been published by sex. The trials report side effects for everyone together, and in all of them the most common ones were stomach effects such as nausea and diarrhea179, mostly mild to moderate in phase 21. The one sex-linked finding so far came from the TRIUMPH-1 presentation: urinary tract infections were more common on retatrutide (6.8 to 8.1%) than on placebo (4.8%), mostly mild to moderate and cleared with treatment, and 92% of them were in women212. Those figures come from the meeting; the published paper's table is the final word.
Commonly reported: appetite dropping in the first weeks, often described as stronger than on tirzepatide, and stomach effects after each step-up that settle within one to two weeks.
Our retatrutide side effects guide has the full rates by dose, and the safety guide covers what the trials found on the pancreas, the heart and the skin sensation called dysesthesia.
What do the retatrutide trials not tell women yet?
- Anything about pregnancy or breastfeeding: both were excluded.
- Results by menopause stage or by hormone therapy.
- A published sex split from phase 3: TRIUMPH-1's came in a meeting talk, and TRIUMPH-2, TRIUMPH-4 and TRANSCEND-T2D-1 give none in their abstracts or, for TRIUMPH-4, its main text9101112.
- Whether women lose more against tirzepatide too: TRIUMPH-5, the head-to-head trial, has not reported16.
Retatrutide is still investigational10, so no regulator has issued a label with a women's section yet. When the TRIUMPH-1 paper's sex tables are public, this guide gets a new review date.
PepVault logs each dose with its date and sends a reminder on dose day, so the record you bring to your doctor is complete. Set reminders in PepVault
Sources
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. PubMed 37366315
- Eli Lilly. The first phase 3 obesity study of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with obesity (TRIUMPH-1). ADA 86th Scientific Sessions, 2026 (Lilly HCP congress page). lilly.com
- ClinicalTrials.gov NCT04881760. A study of LY3437943 in participants who have obesity or are overweight (phase 2; sponsor Eli Lilly and Company). Record and results. clinicaltrials.gov
- Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023. PubMed 37385280
- Urva S et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022. PubMed 36354040
- ClinicalTrials.gov NCT04143802. A study of LY3437943 in participants with type 2 diabetes mellitus (phase 1b; sponsor Eli Lilly and Company). Eligibility criteria. clinicaltrials.gov
- Jastreboff AM et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med. 2026. PubMed 42814954
- Giblin K et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026. PubMed 41090431
- Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026. PubMed 42810372
- Schnitzer TJ et al. Retatrutide once weekly in adults with knee osteoarthritis pain and obesity (TRIUMPH-4 and TRIUMPH-1-OA). N Engl J Med. 2026. Author accepted manuscript (Table 1), White Rose Research Online. PubMed 43001755
- Bajaj HS et al. Efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026. PubMed 42250575
- Evangelou C. Retatrutide reduces body weight by nearly 30% in phase 3 TRIUMPH-1 trial, with gains for sleep apnea and knee pain. Doximity Op-Med, June 16, 2026 (news report of the ADA 86th Scientific Sessions presentation). opmed.doximity.com
- Monostra M. Weight loss varies with investigational triple agonist for adults with obesity. Healio, Endocrine Today (report of the ObesityWeek 2023 presentation). healio.com
- Yang Y et al. Sex differences in the efficacy of glucagon-like peptide-1 receptor agonists for weight reduction: a systematic review and meta-analysis. J Diabetes. 2025. PubMed 40040445
- Sinha B et al. Efficacy and safety of GLP-1 receptor agonists, dual agonists, and retatrutide for weight loss in adults with overweight or obesity: a Bayesian NMA. Obesity (Silver Spring). 2025. PubMed 40685589
- ClinicalTrials.gov NCT06662383. A study of retatrutide (LY3437943) compared to tirzepatide (LY3298176) in adults who have obesity (TRIUMPH-5; sponsor Eli Lilly and Company). Active, not recruiting; no results posted. clinicaltrials.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.